Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma	Tislelizumab (BGB-A317; BGBA-317)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Ramucirumab for Advanced Hepatocellular Carcinoma – second line	Ramucirumab (Cyramza)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2018	View \| Download
Pexastimogene devacirepvec (pexa-vec) for hepatocellular carcinoma – first line	Pexastimogene devacirepvec (Pexa-vec; JX-594)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2017	View \| Download
Pembrolizumab for Hepatocellular Carcinoma – Adjuvant	Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Pembrolizumab for Advanced Hepatocellular Carcinoma – second line onwards	Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2018	View \| Download
Nivolumab-ipilimumab for previously untreated advanced hepatocellular carcinoma	Nivolumab-ipilimumab	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Nivolumab for hepatocellular carcinoma - adjuvant	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2020	View \| Download
Nivolumab (Opdivo) for the treatment of Hepatocellular Carcinoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2017	View \| Download
Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Lenvatinib and pembrolizumab with transarterial chemoembolisation for treating hepatocellular carcinoma	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download